What is Enterin?
Enterin, Inc. is a research-focused entity dedicated to tackling the complexities of neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company's core mission revolves around enhancing patient outcomes through novel findings and insights derived from its research. Enterin aims to serve patients afflicted with Parkinson's disease and healthcare professionals actively seeking advanced therapeutic solutions. Their commitment lies in pushing the boundaries of understanding and treatment for these debilitating neurological conditions.
How much funding has Enterin raised?
Enterin has raised a total of $13.1M across 3 funding rounds:
Series A
$12.7M
Debt
$150K
Debt
$293K
Series A (2017): $12.7M with participation from New Ventures III
Debt (2020): $150K led by PPP
Debt (2021): $293K supported by PPP
Key Investors in Enterin
New Ventures III
New Ventures III is a venture platform specializing in healthcare investments, from startups to established drug companies. Their investment in Enterin suggests a focus on early-stage therapeutic development within the neurodegenerative space.
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Enterin?
With the recent major strategic investment, Enterin is well-positioned to accelerate its research and development initiatives. The substantial capital infusion is expected to fuel advancements in their Parkinson's research, potentially leading to breakthroughs in treatment methodologies. This funding will likely support expanded clinical trials, further scientific exploration, and the scaling of operations to meet the growing demand for innovative solutions in neurodegenerative disease management. The company's strategic direction points towards solidifying its position as a leader in the field.
See full Enterin company page
